Using microarrays to predict resistance to chemotherapy in cancer patients

Pharmacogenomics

Volumn 5, Issue 6, 2004, Pages 611-625

  Lee, Chung Hae ^a   Macgregor, Pascale F ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Canadian Breast Cancer Res Alliance   (Canada)

Author keywords

Anticancer drug resistance; Array comparative genomic hybridization; Chemotherapy; CpG arrays expression profiling; Microarrays

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IMATINIB; METHOTREXATE; MITOXANTRONE; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; VINCA ALKALOID;

CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC KIT; DNA MICROARRAY; DRUG ACTIVATION; DRUG BINDING; DRUG INACTIVATION; DRUG METABOLISM; DRUG TARGETING; GENE TECHNOLOGY; GENOME; LUNG NON SMALL CELL CANCER; PATHOPHYSIOLOGY; PATIENT CARE; PREDICTION; PROMOTER REGION; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 4544325470     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.6.611     Document Type: Review

References (87)

1. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516 (2003).
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002).
3. Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG: Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J. Biol. Chem. 275, 30855-30863 (2000).
4. Gorlick R, Goker E, Trippett T et al.: Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335, 1041-1048 (1996).
5. Longo-Sorbello GS, Bertino JR: Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86, 121-127 (2001).
6. Hipfner DR, Deeley RG, Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359-376 (1999).
7. Doyle LA, Yang W, Abruzzo LV et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95, 15665-15670 (1998).
8. Cole SP, Bhardwaj G, Gerlach JH et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654 (1992).
9. Nooter K, Westerman AM, Flens MJ et al.: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1, 1301-1310 (1995).
10. Yasui K, Mihara S, Zhao C et al.: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 64, 1403-1410 (2004).
11. Cherian MG, Jayasurya A, Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 533, 201-209 (2003).
12. Kawate H, Landis DM, Loeb LA: Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J. Biol. Chem. 277, 36304-36311 (2002).
13. Gorre ME, Mohammed M, Ellwood K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
14. Lonn U, Lonn S, Nilsson B, Stenkvist B: Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 77, 107-112 (1996).
15. Morel F, Bris MJ, Herry A et al.: Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur. J. Haematol. 70, 235-239 (2003).
16. Scappini B, Gatto S, Onida F et al.: Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100, 1459-1471 (2004).
17. Cole S, Tannock IT. Drug resistance. In: The Basic Science of Oncology. McGraw-Hill, New York (2004).
18. Liu LF, Desai SD, Li TK et al.: Mechanism of action of camptothecin. Ann. NY Acad. Sci. 922, 1-10 (2000).
19. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS: Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat. 2, 307-318 (1999).
20. Urasaki Y, Laco GS, Pourquier P et al.: Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res. 61, 1964-1969 (2001).
21. Peterson CL, Cote J: Cellular machineries for chromosomal DNA repair. Genes Dev. 18, 602-616 (2004).
22. Esteller M, Garcia-Foncillas J, Andion E et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
23. Damia G, Guidi G, D'Incalci M: Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur. J. Cancer 34, 1783-1788 (1998).
24. Yamauchi T, Kawai Y, Ueda T: Enhanced DNA excision repair in CCRF-CEM cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea, quantitated using the single cell gel electrophoresis (Comet) assay. Biochem. Pharmacol. 66, 939-946 (2003).
25. Sperandio S, de Belle I, Bredesen DE: An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. USA 97, 14376-14381 (2000).
26. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
27. Debatin KM, Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966 (2004).
28. Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22, 7414-7430 (2003).
29. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
30. Wang D, Urisman A, Liu YT et al.: Viral discovery and sequence recovery using DNA microarrays. PLoS Biol. 1, E2 (2003).
31. Lee JK, Bussey KJ, Gwadry FG et al.: Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol. 4, R82 (2003).
32. Nishizuka S, Chen ST, Gwadry FG et al.: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243-5250 (2003).
33. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS: Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18, 405-412 (2002).
34. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al.: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63, 8614-8622 (2003).
35. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat. Biotechnol. 18, 457-459 (2000).
36. Iscove NN, Barbara M, Gu M et al.: Representation is faithfully preserved in global cDNA amplified exponentially from sub-picogram quantities of mRNA. Nat. Biotechnol. 20, 940-943 (2002).
37. Simon RM, Dobbin K: Experimental design of DNA microarray experiments. Biotechniques (Suppl.), 16-21 (2003).
38. Dobbin K, Shih JH, Simon R: Questions and answers on design of dual-label microarrays for identifying differentially expressed genes. J. Natl. Cancer Inst. 95, 1362-1369 (2003).
39. Novoradovskaya N, Whitfield ML, Basehore LS et al.: Universal reference RNA as a standard for microarray experiments. BMC Genomics 5, 20 (2004).
40. Dobbin K, Shih JH, Simon R: Statistical design of reverse dye microarrays. Bioinformatics 19, 803-810 (2003).
41. Lee ML, Kuo FC, Whitmore GA, Sklar J: Importance ofreplication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc. Natl. Acad. Sci. USA 97, 9834-9839 (2000).
42. Quackenbush J: Microarray data normalization and transformation. Nat. Genet. 32(Suppl.), 496-501 (2002).
43. Leung YF, Cavalieri D: Fundamentals of cDNA microarray data analysis. Trends Genet. 19, 649-659 (2003).
44. Yang YH, Dudoit S, Luu P et al.: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30, E15 (2002).
45. Eisen MB, Spellman PT Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998).
46. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
47. Bullinger L, Dohner K, Bair E et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
48. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc. Nad. Acad. Sci. USA 98, 5116-5121 (2001).
49. Troyanskaya OG, Garber ME, Brown PO, Botstein D, Altman RB: Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics 18, 1454-1461 (2002).
50. Golub TR, Slonim DK, Tamayo P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
51. van 't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
52. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 99, 6567-6572 (2002).
53. Valk PJ, Verhaak RG, Beijen MA et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004).
54. Grosu P, Townsend JP, Hard DL, Cavalieri D: Pathway Processor: a tool for integrating whole-genome expression results into metabolic networks. Genome Res. 12, 1121-1126 (2002).
55. Kallioniemi A, Kallioniemi OP, Sudar D et al.: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258, 818-821 (1992).
56. Solinas-Toldo S, Lampel S, Stilgenbauer S et al.: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20, 399-407 (1997).
57. Ishkanian AS, Malloff CA, Watson SK et al.: A tiling resolution DNA microarray with complete coverage of the human genome. Nat. Genet. 36, 299-303 (2004).
58. Pollack JR, Sorlie T, Perou CM et al.: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. USA 99, 12963-12968 (2002).
59. Kauraniemi P, Barlund M, Monni O, Kallioniemi A: New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 61, 8235-8240 (2001).
60. Clark J, Edwards S, John M et al.: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 34, 104-114 (2002).
61. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP: Genomic microarrays in the spotlight. Trends Genet. 20, 87-94 (2004).
62. Platzer P, Upender M B, Wilson K et al.: Silence of chromosomal amplifications in colon cancer. Cancer Res. 62, 1134-1138 (2002).
63. Ehrlich M, Jiang G, Fiala E et al.: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 21, 6694-6702 (2002).
64. Yan PS, Chen CM, Shi H et al.: Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 61, 8375-8380 (2001).
65. Yan PS, Chen CM, Shi H et al.: Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J. Nutr. 132, 2430S-2434S (2002).
66. Scherf U, Ross DT, Waltham M et al.: A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244 (2000).
67. Kudoh K, Ramanna M, Ravatn R et al.: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166 (2000).
68. Clarke PA, Hostein I, Banerji U et al.: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19, 4125-4133 (2000).
69. Ross DT, Scherf U, Eisen MB et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235 (2000).
70. Staunton JE, Slonim DK, Coller HA et al.: Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787-10792 (2001).
71. Daoud SS, Munson PJ, Reinhold W et al.: Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res. 63, 2782-2793 (2003).
72. Dan S, Tsunoda T, Kitahara O et al.: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62, 1139-1147 (2002).
73. Higuchi E, Oridate N, Furuta Y et al.: Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and CDNA microarray. Head Neck 25, 187-193 (2003).
74. Mariadason JM, Arango D, Shi Q et al.: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63, 8791-8812 (2003).
75. Zorn KK, Jazaeri AA, Awtrey CS et al.: Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin. Cancer Res. 9, 4811-4818 (2003).
76. Boyer J, Maxwell PJ, Longley DB, Johnston PG: 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 24, 417-423 (2004).
77. Hiorns LR, Bradshaw TD, Skelton LA et al.: Variation in RNA expression and genomic DNA content acquired during cell culture. Br. J. Cancer 90, 476-482 (2004).
78. Murata T, Haisa M, Uetsuka H et al.: Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int. J. Mol. Med. 13, 865-868 (2004).
79. Sugimura M, Sagae S, Ishioka S et al.: Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology 66, 53-61 (2004).
80. Whiteside MA, Chen DT, Desmond RA, Abdulkadir SA, Johanning GL: A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 23, 744-752 (2004).
81. Weinstein JN, Pommier Y: Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol. 326, 909-920 (2003).
82. Hess KR, Fuller GN, Rhee CH, Zhang W: Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines. Int. J. Mol. Med. 8, 183-188 (2001).
83. Chang JC, Wooten EC, Tsimelzon A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
84. Ayers M, Symmans WF, Stec J et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22(12), 2284-2293 (2004).
85. Kim HK, Choi IJ, Kim HS et al.: DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem. Biophys. Res. Commun. 316, 781-789 (2004).
86. Bayani J, Brenton JD, Macgregor PF et al.: Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 62, 3466-3476 (2002).
87. Phillips JL, Hayward SW, Wang Y et al.: The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res. 61, 8143-8149 (2001).